Modulación bioquimica del 5 fluorouracil utilizando dosis altas de leucovorin en carcinoma avanzado de colon y recto

Petrelli, Nicholas J; Herrera, Lemuel; Rustum, Youcet; Mittelman, Arnold.
Rev. Inst. Nac. Cancerol. (Méx.) ; 33(2): 355-9, abr.-jun. 1987. tab, ilus
Artículo en Español | LILACS | ID: lil-46632

Documentos relacionados

  1. Even a partial pathological response is associated with lower relapse rates in patients with operable rectal cancer undergoing neoadjuvant chemotherapy.
  2. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.
  3. Anorectal adenocarcinoma recurrence successfully treated with electrochemotherapy: a case report.
  4. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
  5. A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report.
  6. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
  7. The gentamicin-collagen implant and the risk of distant metastases of rectal cancer following short-course radiotherapy and curative resection: the long-term outcomes of a randomized study.
  8. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
  9. Use of Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer.
  10. [A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].